Osteoporosis is an increasing public health problem. The bisphophonates are the most useful treatment used through the world to prevent osteoporotic fractures. Their large prescription revealed an unpredictable side effect: the atypical fracture. These fractures appear in the subtrochanteric or diaphysal femoral proximal site, spontaneously or after a low trauma, and could be bilateral. X-rays shows a transversal or oblique fracture with a spur in the cortex and with a diffuse thickening of the cortical of the proximal femur. Expert's recommendations are current in progress to well understand and managed this problem. Here we report three cases of atypical femur fractures occurred in our Centre of bone diseases with some management and trea...
Atypical fractures are stress fractures that occur frequently in the femur (subtrochanteric or diaph...
Atypical Femoral Fractures (AFF) represent fractures located between the lesser trochanter and the s...
Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures. Atypical femur ...
Osteoporosis is an increasing public health problem. The bisphophonates are the most useful treatmen...
Atypical femur fractures represent a new disease entity associated with the use of oral bisphosphona...
Bisphosphonates (BP) are a commonly prescribed class of drugs for the prevention of osteoporosis-rel...
Atypical fractures of the femur below the lesser trochanter have been reported in patients treated w...
Increasing numbers of atypical subtrochanteric fractures have been reported among long-term bisphosp...
In recent years, bisphosphonates and RANK-ligand inhibitors have become the mainstay of treatment fo...
textabstractBackground: Atypical femur fractures (AFFs) present a rare but serious condition associa...
Osteoporosis and resulting osteoporotic fractures are responsible for significant morbidity, excess ...
Atypical fractures related to the prolonged use of bisphosphonates are caused by low energy mechanis...
To report a case of atypical femoral fracture (AFF) induced by long course of oral bisphosphonates (...
Reports linking long-term use of bisphosphonates (BPs) with atypical fractures of the femur led the ...
Although the existence of atypical femoral fractures is well established and bisphosphonate therapy ...
Atypical fractures are stress fractures that occur frequently in the femur (subtrochanteric or diaph...
Atypical Femoral Fractures (AFF) represent fractures located between the lesser trochanter and the s...
Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures. Atypical femur ...
Osteoporosis is an increasing public health problem. The bisphophonates are the most useful treatmen...
Atypical femur fractures represent a new disease entity associated with the use of oral bisphosphona...
Bisphosphonates (BP) are a commonly prescribed class of drugs for the prevention of osteoporosis-rel...
Atypical fractures of the femur below the lesser trochanter have been reported in patients treated w...
Increasing numbers of atypical subtrochanteric fractures have been reported among long-term bisphosp...
In recent years, bisphosphonates and RANK-ligand inhibitors have become the mainstay of treatment fo...
textabstractBackground: Atypical femur fractures (AFFs) present a rare but serious condition associa...
Osteoporosis and resulting osteoporotic fractures are responsible for significant morbidity, excess ...
Atypical fractures related to the prolonged use of bisphosphonates are caused by low energy mechanis...
To report a case of atypical femoral fracture (AFF) induced by long course of oral bisphosphonates (...
Reports linking long-term use of bisphosphonates (BPs) with atypical fractures of the femur led the ...
Although the existence of atypical femoral fractures is well established and bisphosphonate therapy ...
Atypical fractures are stress fractures that occur frequently in the femur (subtrochanteric or diaph...
Atypical Femoral Fractures (AFF) represent fractures located between the lesser trochanter and the s...
Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures. Atypical femur ...